Don't worry bout the mule, just load the wagon.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Johanna Richlin [here tis again, skeptical moms]
Article on vaccine skeptical Mothers
https://theconversation.com/vaccine-skeptical-mothers-say-bad-health-care-experiences-made-them-distrust-the-medical-system-217433
Assistant Professor of Anthropology, University of Maine
I specialize in the anthropology of religion and psychological and medical anthropology, with expertise in evangelical Christianity in the U.S. and Brazil, U.S. migration, studies of affect and emotion, and gender, health and society.
My first research project explored the impact of U.S. migration experience on the varied religious beliefs, choices, and sentiments of Brazilian migrants in the Washington, D.C. metropolitan region. From this body of research, I published a research article in Current Anthropology, entitled “The Affective Therapeutics of Migrant Faith: Evangelical Christianity among Brazilians in Greater Washington, D.C” (2019), and completed my first book, In the Hands of God: How Evangelical Belonging Transforms Migrant Experience In the United States (Princeton University Press, 2022). My research was reviewed in The Economist (“Religion and Vulnerability: Why Charismatic Christianity is Popular with Migrants” (2019)) and featured on The Chris Voss Show (2022).
My current research investigates U.S. healthcare experience and vaccine beliefs, behaviors, and solidarities among diverse demographics. The first publication related to this project, “From Iatrogenesis to Vaccine Skepticism: U.S. Mothers’ Negative Vaccine Perceptions and Non-vaccination Practices as Reverberations of Medical Harm,” was published last spring (2023) in Medical Anthropology Quarterly.
Experience
2023–present
Assistant Professor, University of Maine
2019–2023
Assistant Professor, University of Oregon
Education
2016
Stanford University , PhD, Cultural Anthropology
LOL, I thought he/she was a professor with a pronoun title. Sounds like our resident statistician and johnny come lately investigator.
I would bet TRUE.
https://www.thegatewaypundit.com/2024/03/they-lied-you-new-study-finds-people-who/
If they lied about the jabs and the alternative remedies, what comes next?
$CYDY$ 2024
Take some leronlimab for your scrambled brain. Wrong post. But what's new?
LOL, they skipped over that part. LMAO.
Wonder if they know there is a new sheriff in town?
$CYDY$
Pretty sure you didn't read and listen to the PR's very closely.
Young pigeons fed by their basher bosses can only regurgitate, not think.
Leronlimab works and is safe. Pretty simple. Watch them disappear overnight
once any BP company collaborates with CytoDyn. Poof, they are gone.
$CYDY$ 2024
LOL, did you slide off the Pig? Yes or no? Scratching the bottom of the barrel lately?
$CYDY$ 2024
Ok Lil Elf Farrago. You da man?
LMAO
$CYDY$ 2024
Happy Birthday Niknak1
Let us know your symptoms and perhaps we can recommend some extra boosters and a double dose of rendesivir.
Have a lovely weekend.
$CYDY$ 2024
OMG the Ihub conspiracy master blaster! What? You haven't read and analyzed the company? How about that,
When I read back over your history, not once have I found anyone who likes you or values your "research" with
the exception of your fellow paid bashers, naturally.
Carry On Circle Jerk.
$CYDY$ 2024
The reason leronlimab did not get approved is three fold.
1. It does not cause enough bodily harm with long lasting side effects
2. It was not trending
3. CytoDyn did not fork over the club dues
$CYDY$ 2024
Hey JackASS, you haven't told one thing right the whole time you are on IFlub. Believing in a company and buying the stock does not equate to pumping like you do. You pump your bash with Janet Shell along with your other basher buddies. Are you the leader of this circle jerk? What a groupie!
Piss off liar. Put that in your crack pipe and take a heavy drag.
Amen to that. This new AI is going to be a real mess I do believe while also delivering some good.
Reminds me of the drunk in the bar who told the hospital gal with a hot body sitting across from him, "darling, your face would stop a clock", while his buddy remarked ......."sweetie, your presence makes time stand still". He woke up with the nurse the next morning sporting a big smile, while his friend was at home nursing a hang over.
https://www.theepochtimes.com/health/pfizer-and-moderna-covid-vaccines-efficacy-exaggerated-effectiveness-well-below-50-percent-researchers-say-5595590?src_src=morningbriefnoe&src_cmp=mb-2024-03-07&est=AAAAAAAAAAAAAAAAdbAmeh0exsTo9bIGsWoXCLt3DMv%2BeZd%2FEugtIdyHPONOLA%3D%3D
And they had FDA/CDC run cover for them and stop all others like leronlimab/Ivermectin/HCQ
Bend over paid bashers. Let Phuzzy Phizer and Mo dern it blow more smoke up your wazooo.
Health News
COVID News
Pfizer and Moderna COVID Vaccines’ Efficacy Exaggerated, Effectiveness ‘Well Below’ 50 Percent, Researchers Say
A key problem with the clinical trial is that the definition of vaccinated and unvaccinated is unclear, the paper says.
Researchers allege that biases and manipulation of Pfizer and Moderna COVID-19 vaccine clinical data have exaggerated vaccine efficacy and underestimated vaccine adverse events.
While most clinical trials would evaluate the effects of a drug from the day it is administered, these COVID-19 mRNA vaccines are not being evaluated from the first day the vaccines are given. A later date is chosen, which inflates the vaccine’s perceived efficacy and safety, researchers say.
It could make an ineffective vaccine — a COVID vaccine with zero efficacy — have a perceived vaccine effectiveness of up to 48 percent, said researcher Raphael Lataster on Feb. 26, citing a paper authored by professor Peter Doshi from the University of Maryland and others.
Unclear Definitions of Vaccinated vs. Unvaccinated
Mr. Lataster, associate lecturer at the University of Sydney, spoke at Sen. Ron Johnson’s (R-Wis.) Feb. 26 roundtable discussion on COVID-19 vaccines and public health messaging. He summarized findings from a collection of four commentaries published in a peer-reviewed journal, of which two were authored by him.
“We have found in the studies varying definitions of fully vaccinated and unvaccinated. Generally what we find is that they are ignoring COVID infections in the partially vaccinated,” Mr. Lataster said.
“In randomized trials, it is customary to define ‘time zero’ as the point in time, for each trial participant, when eligibility criteria are met, treatment is assigned, and follow-up begins,” Mr. Doshi and another author wrote in one of the papers.
Instead, COVID cases in vaccinated individuals are only counted weeks after a person is vaccinated. In Pfizer’s clinical trials, a person is considered vaccinated and their COVID cases are counted a week after they received the second dose, whereas in Moderna’s clinical trials, a person is considered vaccinated two weeks after their second dose.
By substituting some of Pfizer’s phase 3 clinical data and defining a person as vaccinated or unvaccinated according to Pfizer’s criteria in the clinical trials, Mr. Doshi and his authors found that Pfizer clinical trial could inflate a vaccine with zero efficacy to 48 percent. Their finding was published in the Journal of Evaluation in Clinical Practice.
Additionally, they found that this hypothetical number could further inflate to 67 percent due to other real-life factors during vaccine rollouts.
As older people were more likely to get vaccinated early on due to being more at risk of infections, this may reduce the perceived vaccine efficacy.
However, people were getting vaccinated at the time when COVID cases were peaking and people were generating natural immunity to the virus. The subsequent decline in COVID cases coincided with increased vaccination rates, which would then inflate perceived vaccine efficacy, according to the paper.
Millions of Lives Saved Based on Modeling
The COVID-19 mRNA vaccines have been promoted to have saved millions of lives. However, Mr. Lataster said that those statements may not reflect what happened in real life.
Mr. Lataster has been invited to partake in a study reviewing whether the mRNA vaccines have saved millions of lives.
“There are many problems we found, over twelve issues with how the data is utilized and estimated. For one thing, it’s [based on] a model and the map is not the territory,” Mr. Lataster said. The study is currently unpublished.
He said that they have also been looking at verifying claims that COVID-19 vaccines reduced severe disease, hospitalizations, and deaths.
One of the problems that has been identified is that most of these studies do not define or have different definitions of what counted as a vaccinated person.
Significant Number of Unconfirmed COVID Cases
According to an FDA briefing document, Pfizer acknowledged “3410 total cases of suspected but unconfirmed COVID-19 in the overall study population.”
These suspected cases were split almost evenly between the treatment and placebo groups.The Pfizer vaccines were estimated to have over 90 percent vaccine efficacy because while 850 out of around 22,000 people in the placebo group contracted COVID, only 80 out of 22,000 vaccinated participants contracted COVID. This difference in proportion of COVID cases is how the researchers calculated the vaccine efficacy.
However, if all of the suspected cases were indeed COVID-19 cases, having a similar proportion of COVID-19 cases between the treatment and placebo group “would have drastically brought down treatment efficacy estimates,” Mr. Lataster wrote in his commentary.
“In any case, you can argue that figure is well below the 50 percent required for approval,” Mr. Lataster said.
Underrepresented Adverse Events
While Pfizer and Moderna phase 3 clinical trials followed adverse events from the day of vaccine administration, they defined an individual as vaccinated only if several weeks had passed following vaccination.
Therefore, some of the adverse events that may have occurred soon after vaccination and would therefore be more strongly linked to vaccination would not be attributed to the vaccine, leading to underestimated adverse event rates. Also, the recording of the adverse events is mostly reliant on unsolicited reporting by vaccine participants, especially for serious adverse events, according to Pfizer’s fact sheet for health providers. If the participant dies following the COVID-19 vaccine, the trial researchers may be unable to track this since they need reporting from the participants, according to Mr. Lataster.
COVID vaccination adverse event reports to the Vaccine Adverse Event Reports System show that more than 12 percent of deaths occurred on the day or the day after vaccination.
Furthermore, the placebo group was later given the COVID-19 vaccines, effectively “unblinding” them. This meant that researchers would be unable to compare the placebo and the vaccine group for potential long-term safety signals.
The Epoch Times reached out to Pfizer and Moderna for comments.
Marina Zhang
Marina Zhang
Author
Marina Zhang is a health writer for The Epoch Times, based in New York. She mainly covers stories on COVID-19 and the healthcare system and has a bachelors in biomedicine from The University of Melbourne. Contact her at marina.zhang@epochtimes.com.
Too bad they are not paid based on merit. Something kind of like a floating mortgage wouldn't be a bad idea.
Funny your trolling opinion isn't worth a shit and never has been.
Excellent analysis. Gave you a follow.
They do, the investment world never runs out of cash..or bitcoin or gold. Stand ready, this stock will rumble this year.
Oh yes, thanks AmarX for your help!!! ( Ain't it nice having the lawsuit PREPAID...eat em up Sidley )
$CYDY$ 2024
" Lazerson has been involved in the mineral exploration and technology industries for 25 years. In 2018, Mr. Lazerson accepted the Standard & Poors Global - Platts Metals Award for Leadership in Base and Specialty Metals on behalf of MGX Minerals as its CEO. As CEO, Mr. Lazerson oversaw the financing of $60M in direct lithium extraction (DLE) and zinc-air battery technologies as well as exploration for magnesium, silicon, and gold including the discovery of the 8.1Mt Measured + Indicated Driftwood Creek Magnesite deposit with an in situ value of approximately $1.8B. In addition, Mr. Lazerson has been involved in diamond exploration while CEO of Margaret Lake Diamonds and a Director of Arctic Star Exploration and lithium exploration while at MGX and as a Director of Far Resources (now Foremost Lithium). Mr. Lazerson holds a BA in International Relations from the University of Pennsylvania."
Betcha we see some action!
Wish I had PM again, but until some better understanding with Admin comes about. it will have to wait.
Wouldn't if be something if rs is canceled? It does happen. Or it happens and is followed by other news
which propels the share price. This happened to me more than a few times with very similar set up with
the pps sitting on the bottom. So IMO it is a gamble either way but with a good chance either event can
be profitable. No matter, the company is making progress in proving up the value of the mineral properties in a mineral friendly country. I do think there are some good plans evolving to be revealed this year.
These junior miners can be quite lucrative. Sitting on the bottom before a launch is more than fun. Regardless,
when it comes to Risk v. Reward it appears worth the money to me.
North Bay Resources Inc. (NBRI.NaE) is a junior mining company with current operations in British Columbia, Canada. The Company holds 100% ownership of several significant mining properties, including Wolf Lake Gold, the Murex Copper Project on Vancouver Island, and the Tulameen Platinum Project near Princeton, BC.
Anyone of these are ripe for partnership, sale, or joint mining venture.
or.... fore! And hopefully the ball is on the green and not in the rough.
I just hope we get some sales that are not just flimsy set up fees or commissions. Hopefully, we get more than a glimpse of what could be coming from projects in the works presently, and from those in planning stage. Will it be more of the same and just hot air? Many seem to feel the time is ripe for seeing some meat on the bone. It would be a welcome change long overdue!
LAKE FOREST, Calif.--(BUSINESS WIRE)-- Liquidmetal® Technologies, Inc. , Liquidmetal® Technologies, Inc., the world’s leading developer of amorphous alloys and composites, will hold its year-end earnings conference call on Tuesday, March 12th, at 4:30 p.m. Eastern time. Liquidmetal Technologies (LQMT.NaE) CEO Tony Chung will host the call.
Please Dial in 5-10 minutes prior to the start time using the information below:
Date:
Tuesday, March 12th, 2024
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Conference Call this next Tuesday 12 March. Maybe we hear about that twitter post in China!
yes it would. agreed.
How many times have we seen this.... up and down. Your glass is half empty while ours is half full. Get it?
Great buying opps is what I like about the negative nellies. Little by little more green and more full! Love those bags.
Thanks loads!!
$CYDY$ 2024
Justin Keister MS DABR
@justinkeister5
IHub got so bad with misinformation that I quit reading that stuff. A large congregation of paid shills.
Gone from this site because of paid shills.
How much again did you say you made?
$CYDY$ 2024
Yes, perhaps but don't forget we have growing interested parties that will want to collaborate in one way or another in studies paired to their drugs. These partnerships will be structured so they are sharing in the costs, and sometimes mergers take place in these instances or even buy outs. This year we may well see a few shared studies as well as trials beginning. Most of all, we will see progress on the AmarX lawsuit in August.
Your assumptions are basically correct. Most of us believe this is a long term hold and prices now are dirt cheap as you say. So depending on ones investment idea here, some may be satisfied with the pps at a buck. Time wise I think viewing the prospects of new studies and trials alone will take us back to .50 or beyond easily this year. Added to that the above mentioned AmarX and/or collaborations the pps may well go over a buck or much higher without difficulty.
Additionally, the artificial intelligence study being conducted may well prove extremely valuable especially as to a more enhanced longer acting version of leronlimab. That will result in new patents. Big investors regard patents and critical personnel as the key that unlocks their coffers.
$CYDY$ 2024
https://www.reuters.com/business/finance/elliott-management-plans-spend-over-1-bln-mining-assets-ft-reports-2024-02-23/
At current prices it is a fortune. Anyone think gold is going down anytime soon?
Salary cuts but nice chuck of shares in exchange. These guys need minimum wage with no shares until some successes are confirmed.
https://www.acrobiosystems.com.cn/A1288-Cytokine.html
Lots of focus gaining on our area of expertise.
$CYDY$ 2024
This should be a great year for their development. 2024 is looking pretty good thus far.
Lol, sure thing pig rider. All are still watching and trading, many gone on to better platforms.
Hang on to your jackass. It gets bumpy occasionally in the OTC.
Don't forget, Zerub was awarded the grand prize by King Darius. Why?
$CYDY$ Leronlimab the real deal, CytoDyn where truth wins out.
2024
How much? Experience and minerals in the ground with more being discovered.
Check out the latest.
SKIPPACK, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- North Bay Resources Inc. (NBRI) (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce previously unreleased assays (with the exception of sample #H619241) at its wholly owned Murex Copper Project (formerly Mt. Washington).
Fall 2023 Exploration consisted of geochemical and geological mapping in the North of the property, yielding the following assays:
#H619230 22.2g/t gold, 48.0g/t silver, 0.63% copper, 8.11% zinc
#H619231 5.11g/t gold, 24.4 silver, 0.93% copper, 0.42% zinc
#H619232 1.18g/t gold, 71.8g/t silver, 3.12% copper, 0.27% zinc
#H619241 60.3g/t gold, 141g/t silver, 0.62% copper, 6.76% zinc
#H619233 and #H619234 were outside the mineralized zone
Fall 2023 Exploration consisted of 6 rock chip samples covering the Lupus and Lakeview Zones. Rock chip sampling consisted of geochemical analysis at ALS Chemex Labs, North Vancouver, B.C. ALS method ME-MS61, ME-OG62, Cu-OG62, Zn-OG62, PGM-MS23, As-OG62, and Au-AA25.
Historic Exploration
Although completed by qualified Geologists and Engineers, historic results are not NI-43101 compliant.
In addition, to the gold and polymetallic zones in the North of the property, the Murex breccia zones are located in the central part of the property and are interpreted as a collapsed volcanic dome structure with shallow-dipping thrust faults cut by steeply dipping faults associated with polymetallic Cu-Ag-Au-As-Sb-Mo-Te bearing sulphide mineralization. Historic work identified a 700m X 700m area, the D Zone, along with the A Zone and E Zone, two breccia zones within a 1,200m X 3,000m area.
The property has been systematically explored, since 1957, by various operators including Noranda, now Glencore. Extensive previous exploration has occurred with the following significant drill intercepts:
Hole 69-10
82.3m @ 0.20% copper, 0.015% molybdenum and 3.3 g/t silver from surface to 82.3m
Hole 69-14
27m @ 0.22% copper, 0.005% molybdenum and 3.4 g/t silver from surface to 27.4m
Hole 73-3, assayed for copper only
120.2m @ 0.24% copper from 3.2m to 123m
Hole 73-6, assayed for copper only
60.3m @ 0.20% copper from 2.6m to 62.9m
Hole 74-2
46.5m @ 0.53% copper, 0.17g/t gold and 7.2g/t silver from 9.1m to 55.6m and
30.0 m @ 0.245% copper, 0.003g/t gold and 4.1g/t silver from 62.9m to 89.9m
Hole 74-3
57.1m @ 0.058% copper, 0.73g/t gold and 2.1g/t silver from 0m to 57.2m
Hole 86-1
16.0m @ 6.1 g/t gold, 4.2g/t silver and 0.17% copper from 1.5m to 17.5m
Hole 86-7
19.8m @ 0.22g/t gold, 9.9g/t silver and 1.5% copper from 29.4m to 49.2m and
6.8m @ 0.38 g/t gold, 21 g/t silver and 3.3% copper from 55.5m to 62.3m
Hole 86-1
16.0m @ 6.1g/t gold, 4.2g/t silver and 0.17% copper
Hole 88-19
16.0m @ 6.1g/t gold, 4.2g/t silver and 0.17% copper
There has been extensive trenching and surface sampling at the Murex zones grading up to 9% copper and over 100g/t gold.
Copper Island Project
The Company has completed exploration at the Copper Bell Zone where Summer 2023 Exploration resulted in assays up to 14.7% copper (see Press Release dated February 16th, 2024). Geological mapping and assays are now pending.
Qualified Person
Andris Kikauka (P.Geo) is a Qualified Person in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects, and has reviewed and approved the scientific and technical content of this news release.
On behalf of the Board of Directors of
NORTH BAY RESOURCES INC. (NBRI)
Jared Lazerson
CEO
jared@northbay-resources.com
northbay-resources.com
215-661-1100